title: [Novel Therapeutic Interventions in Guillain-Barré Syndrome: Review and Future Perspective].
abstract: Intravenous immunoglobulin (IVIg) and plasma exchange (PE) are of proven efficacy and are considered the standard therapy for Guillain Barré syndrome (GBS). However, some patients require artificial ventilation during the acute phase and experience long-lasting neurological deficits or symptoms. Currently, there is no established therapeutic intervention for GBS other than IVIg and PE, even though a number of compounds have been investigated. Clinical trials to investigate the efficacy and safety of a second IVIg or eculizumab are ongoing. Increased understanding of the pathophysiology of GBS is expected to contribute to the development of a novel therapeutic approach.
authors.affiliation: Department of Neurology, Graduate School of Medicine, Chiba University.
authors.forename: Sonoko
authors.initials: S
authors.lastname: Misawa
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D020275:Guillain-Barre Syndrome / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D017063:Outcome Assessment, Health Care / Q000379:methods; D010951:Plasma Exchange / Q000379:methods; D012121:Respiration, Artificial / Q000379:methods
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D016756:Immunoglobulins, Intravenous; C481642:eculizumab